Prevalence of HIV Drug Resistance, its Correlates and Common Mutations Amongst people living with HIV in Northern Uganda. A Cross-Sectional Study.

Kayinda Francis[1,2] , Awor Phyllis[1] , Twaha Mahaba[2] , Alex Muganzi[2], Joanita Kigozi[2], Odong Olwedo Patrick[3] , Esther M Nasuuna[2], Robert Mutumba[4], Rhoda Wanyenze[1]

1. Makerere University, School of Public Health, Kampala, Uganda.
2. Infectious Diseases Institute, College of Health science, Makerere University, Kampala, Uganda.
3. Medical Department, Yumbe Regional Referral Hospital, Yumbe, Uganda.
4. STD/AIDS control program, Ministry of Health, Kampala, Uganda.

Corresponding author

Francis Kayinda kaysfrancis@gmail.com, fkayinda@idi.co.ug

Abstract

Background: HIV drug resistance (HIVDR) poses a challenge to the management of people living with HIV (PLHIV), particularly among those experiencing virologic failure. The West-Nile region of Uganda faces HIV treatment challenges and has a high virological failure rate. We sought to estimate the prevalence of HIV drug resistance, describe the HIV drug resistance mutations and evaluate the factors associated with HIVDR among PLHIV with a viral load of ≥1000 copies/mL in the region.

Methods: We conducted a cross-sectional analysis of HIVDR data of Non suppressed PLHIV receiving Anti-retroviral therapy (ART) within the region whose HIVDR tests were conducted between January 2021 to December 2023. Demographic and clinical data was extracted from the National HIVDR database. We characterized PLHIV and used logistic regression models to determine factors associated with HIVDR.

Results: A total 295 participants records were analyzed where, 133 (45.1%) were adults of 25+ years and 167 (56.6%) were female, the median age was 19 years (interquartile range [IQR]: 3–74 years), and median duration on ART was 8 years (IQR: 1–19 years). Overall, 73.9% (218/295) had HIVDR mutations with 66% of subjects having Non-nucleoside reverse transcriptase mutations. M184V/I (50%), K103N (34%) and TAMS (26%) were the commonest mutations. High rates of resistance to Etravirine (27%) in comparison to other third-line candidate drugs of Dolutegravir (12%) and Darunavir (5%) was also observed. Long duration on ART was associated with presence of HIVDR mutations (aOR=; 1.15 95%CI 1.05 -1.26 p=0.003).

Conclusion: The high HIVDR prevalence in the region, although lower than previous Ugandan reports, underscores the need for routine adherence support VL monitoring and surveillance through genotypic resistance testing to avoid unnecessary switching of PLHIV to costly second-line or third line regimens. High Etravirine resistance reflects past NNRTI reliance, while increasing Dolutegravir resistance may stem from unintended monotherapy due to its pairing with failing NRTIs. Low Darunavir resistance is attributed to its strong genetic barrier.

Keywords: HIV, ART, Viral load, HIVDR, Resistance, Mutations, Uganda.

Introduction

HIV remains a major global epidemic with 39.9 million people living with HIV (PLHIV) by the end of 2023, including 1.3 million new infections and over 630,000 deaths (1). Sub-Saharan Africa (SSA) bears the largest burden, with 25.9 million PLHIV (1, 2). Uganda had an estimated 1.5 million PLHIV in 2023 with 38,000 new HIV infections and 20,000 deaths (3).

Antiretroviral therapy (ART) has significantly improved health outcomes for PLHIV who achieve HIV viral suppression through maintaining immune function which leads to decreased mortality and morbidity from opportunistic infections. It also helps achieve epidemic control

through the principle of undetectable = untransmissible (U=U) (4). Uganda is among the SSA countries that have made significant progress in increasing ART coverage and reducing HIV-related deaths (3). Uganda has achieved a treatment coverage rate of 84%, however, the national viral suppression rate estimated at 79% is below the Joint United Nations Program for AIDS (UNAIDS) 95-95-95 target (1, 5).

ART effectiveness is threatened by the emergence of HIV drug resistance (HIVDR). HIVDR is when mutations in the genetic structure of HIV happen and affect the ability of ART drugs to inhibit viral replication (6, 7). HIVDR is one of the key barriers in attainment of viral suppression and if not addressed, it could result in millions of deaths, a rise in new, difficult-to-treat variants, and higher healthcare costs due to switching to more expensive regimens that are also associated with greater toxicity (8). The global prevalence studies on HIVDR include one by World Health Organization (WHO). This was conducted between 2004 and 2021 in 66 countries including Uganda, and a prevalence of 83.1% was obtained amongst adults on first line of treatment with viral load (VL) of >1,000copies/ml (9). In Uganda, a national survey conducted in 2018 obtained a high HIVDR rate of 90.4% amongst non-suppressed PLHIV in care (10), however other studies conducted in Uganda have reported lower rates ranging from 73.2% to 84.6% (11-13).

The West Nile region of Uganda has an HIV viral suppression rate of 77%, lower than the national average (5), and has unique factors such as significant refugee population (22%), mobile and migrant communities, bordering conflict-affected countries (South Sudan and Democratic republic of Congo), and high levels of poverty. All of these create social, economic, and health vulnerabilities (14-16). There is limited data on the prevalence, specific mutations, and associated factors for HIVDR in this region. This study estimated the prevalence of HIVDR,

described common mutations, and associated factors among non-suppressed PLHIV in the West Nile region of Uganda.

Materials and Methods

Study design and Participants

This was a cross-sectional study conducted within the West-Nile region of Uganda in the 161 health facilities that offer comprehensive ART services (17). The region had a population of 3.6 million people in 2023 and an estimated 49,000 PLHIV (15). Study participants included PLHIV on ART for at least one year with non-suppressed HIV viral load (>1000 copies/ml) who had HIVDR test from 1st January 2021 to 30th December 2023.

HIV drug resistance testing in Uganda

All PLHIV on ART in Uganda receive a VL test annually. Those with a non-suppressed VL undergo intensive adherence counselling (IAC) for three months with a repeat VL at the end. Individuals with a persistent non- suppressed VL are eligible for an HIVDR test. A Plasma or dried blood spot (DBS) sample is collected and referred to the HIVDR testing facility at a central national laboratory. Here, RNA extraction is done using commercial kits followed by reverse transcription, PCR amplification and finally sequencing where individual mutations are identified using either Sanger sequencing or Next generation sequencing. Mutations are identified and interpreted using the Stanford HIV drug resistance database (18-20). The results of the HIVDR test are uploaded onto the national database together with the patients clinical and demographic information.

Data collection

Census sampling was used to include all PLHIV with HIV DR results. A pretested data abstraction tool was used to collect demographic and clinical data. Data was accessed from the

national database on 16th May 2024. Demographic data included age and sex. Clinical data included viral load copies preceding the DR test, WHO clinical stage, regimen class at the time of sample collection, nucleoside reverse transcriptase inhibitor (NRTI) anchor drug of the regimen, the full ART regimen, duration on ART, the line of ART treatment, indication for the HIVDR test, year of HIVDR test and actual mutations per participant. A mutation was classified as drug resistant if it had a penalty score ≥15 assigned to an ARV drug using the Stanford HIV database algorithm version 9.0 (20) and a relative abundance of ≥ 20% (21). A penalty score is the value assigned to each HIVDR mutation to estimate the level of resistance it brings to a particular drug. Penalty scores of 0-9, represent no resistance; 10-14 represent potential low-level resistance; 15-29 represent low level resistance; 30-59 represent intermediate resistance and scores of ≥ 60 represent high level resistance (20)

Ethics approval and consent to participate

This study was conducted in accordance with ethical principles of the Helsinki declaration. Institutional ethical approval was obtained from the Makerere University School of Public Health Research and Ethics Committee with reference number 366. Permission to use national data was granted by the Ugandan Ministry of Health through the Director General, Health Services. The study used de-identified secondary data, and the authors did not have access to information that could identify individual participants during or after data collection, hence the need for individual participant consent was waived by the ethics committee. All filled forms were kept safely in a waterproof locked cabinet where they could only be accessed by the principal investigator.

Data Analysis

We performed statistical analysis using Stata SE version 14.2, developed by Stata Corp LLC in the United States. To assess the distributions of the independent variables (clinical and demographic), we used medians (and IQRs) for the continuous variables and frequencies and proportions for the categorical variables. The dependent variable was presence of at least one HIVDR mutation. We performed a bivariable logistic regression analysis to assess association of each of the independent potential correlates with the outcome. Variables that had an odds ratio (OR) with $P \leq 0.2$ were included in multivariable logistic regression model together with age and sex as potential confounders. Results were presented as adjusted odds ratios (aORs) with 95% confidence interval (CI). Variables were considered significantly associated with the outcome if the P value for the aOR was less than or equal to 0.05.

Results

During the study period , 363 PLHIV had a repeat non suppressed viral load but only 295 (81.3%) had HIV DR results and were considered for the study **(Fig 1).** Of the 295 participants, 167 (56.6%) were female, with a median age of 19 years. They had been on ART for a median 8 years **(Table 1).**

Table 1: Baseline Participant characteristics

Characteristic		**Frequency (%)**	**Number with HIVDR mutations (%)**
Gender	F	167 (56.6)	124 (74.3)
	M	128 (43.4)	94 (73.4)
Age Group	<10 years	37 (12.5)	30 (81.1)
	10-19 years	113 (38.3)	84 (74.3)
	20-24 years	12 (4.1)	7 (58.3)
	25+ years	133 (45.1)	97 (72.9)
NRTI Anchor at time of sample	ABC/3TC	87 (29.5)	67 (77.0)

collection	AZT/3TC	78 (26.4)	64 (82.1)
	TDF/3TC	130 (44.1)	87 (66.9)
Type of regimen at time of sample collection	NNRTI	17 (5.7)	13 (76.5)
	PI	103 (34.9)	86 (83.4)
	INSTI	175 (59.3)	118 (67.4)
ART regimen at time of sample collection	TDF/3TC/DTG	103 (34.9)	63 (61.2)
	AZT/3TC/DTG	35 (11.9)	29 (82.9)
	ABC/3TC/DTG	37 (12.5)	26 (70.3)
	ABC/3TC/LPVr	45 (15.3)	37 (82.2)
	TDF/3TC/ATVr	12 (4.1)	10 (83.3)
	AZT/3TC/ATVr	21 (7.1)	17 (81.0)
	OTHERS	42 (14.2)	36 (85.7)
VL Leading to the HIVDR test (copies/ml)	1,000-9,999	92 (31)	63 (68.5)
	10,000-99,999	128 (43.4)	102 (79.7)
	100,000-999,000	66 (22.4)	45 (68.2)
	1,000,000 +	09 (3.1)	08 (88.9)
Treatment Line	First line	145 (49.2)	94 (64.8)
	Second line	138 (46.8)	113 (81.9)
	Third line	12 (4.0)	11 (91.7)
HIVDR Indication	Children failing on 1st line	34 (12)	27(79.4)
	Adolescent failing on 1st line	44 (15)	32 (73)
	Adult failing on 1st Line	67 (23)	35 (52)
	Patients failing on 2nd Line	138 (47)	113 (82)
	Patient failing on 3rd line	12 (4)	11 (92)
WHO clinical stage	I/II	242 (82)	175 (72.3)
	III/IV	53 (18)	43 (81.1)
Year of Sample collection	2021	51 (17.3)	46 (90.2)
	2022	51 (17.3)	43 (84.3)
	2023	193 (65.4)	129 (66.8)
	Median	**IQR**	
Age (years)	19	3 – 74	
Duration on ART (years)	8	1 – 19	
VL at DR testing (copies/ml)	253,000	1,040 – 2,635,340	

Presence of HIVDR mutations

HIVDR mutations were present in 218 (73.9%: 95% CI 68.9–78.9%). Sixty six percent (66%) of participants had NNRTI mutations while 55% had NRTI mutations **(Table 2)**. HIVDR mutations were observed across different drug classes in the same individuals where 55% (161) of all participants had resistance to at least two drug classes; 20% (59) had to at least three drug classes and 1% (03) of the participants had resistance across all the 4 drug classes. The commonest cross resistance was observed between NNRTI and NRTI drug classes (67%)**.**

Table 2: HIVDR Mutations according to drug classes

Regimen	**Number and Proportion of HIVDR Mutations amongst all 295 participants.**
NNRTIs	196 (66%)
NRTIs	161 (55%)
PIs	46 (16%)
INSTIs	40 (14%)
Total	**218 (73.9%)**

HIVDR Mutations amongst participants.

The M184V was the commonest mutation observed in NRTI class appearing amongst 146 (50%) participants. The thymidine analogue mutations (TAMs) were observed amongst 77 (26%) participants and Type 2 pattern TAMs were more common (56% of all TAMs) than type 1 pattern TAMs. K65R was only observed amongst only 4 (1%) participants. Amongst NNRTIs, K103N/S mutations were the commonest appearing amongst 99 (34%) participants. Overall, 81 (27%) participants had resistance to Etravirine. The darunavir sparing M46V/A mutations were the commonest amongst Protease Inhibitors (PIs) appearing in 20 (7%). Overall, 14 (5%) participants had resistance to darunavir. The E138K/A and G118R mutations were the commonest amongst Integrase strand transfer Inhibitors (INSTIs) occurring in 18 (6%) and 12

(4%) participants respectively and in total 35 (12%) participants had resistance to Dolutegravir (DTG). 24 (8%) participants had a mixture of wild type virus with the mutated virus **(Fig 2).**

Factors associated with HIVDR

Duration on ART, indication for the HIVDR test and the year of HIVDR sample collection were independently associated with HIVDR mutations. The odds of HIVDR significantly increased for every year an individual spends on ART (aOR=; 1.15 95%CI 1.05 -1.26 p=0.003). For the indication for the HIVDR test, adolescents failing on first line (aOR=; 4.60 95%CI 1.21-17.43 p=0.025), participants failing on 2nd line (aOR=; 3.90 95%CI 1.25-12.20 p=0.019) and participants failing on third line (aOR=; 10.95 95%CI 1.02-117.49 p=0.048) were found to be significantly associated with HIVDR. The HIVDR tests conducted in 2023 (aOR=; 0.21 95%CI 0.07 - 0.69 p=0.01) were also significantly associated with HIVDR **(Table 3).**

Table 3: Factors associated with HIVDR mutations

		Bivariate Analysis		**Multivariate analysis**	
Characteristic		OR (95% CI)	*p*-value	*Adjusted OR (95% CI)*	*P-Value*
Duration on ART	8 years (Median)	1.15 (1.06-1.23)	**0.001**	*1.15 (1.05-1.26)*	***0.003****
Gender	F	1.04 (0.62-1.76)	0.875	-	-
	M	Referent		-	
Age Group	<10 years	Referent		-	-
	10-19 years	0.68 (0.27- 1.70)	0.406	-	-
	20-24 years	0.33 (0.08-1.34)	0.120	-	-
	25+ years	0.63 (0.25 - 1.56)	0.316	-	-
NRTI Anchor at time of sample collection	ABC/3TC	1.66 (0.89-3.07)	0.110	*1.38 (0.54-3.55)*	*0.503*
	AZT/3TC	2.26 (1.14-4.48)	**0.02**	*1.28 (0.50-3.32)*	*0.606*
	TDF/3TC	Referent		-	-
Type of regimen at time of sample collection	NNRTI	2.25 (0.62-8.16)	0.216	*1.00 (0.22-4.52)*	*0.992*
	PI	2.44 (1.32-4.49)	**0.004**	*0.65 (0.26-1.64)*	*0.361*
	INSTI	Referent		-	-

ART regimen at time of sample collection	TDF/3TC/DTG	Referent		-	-
	AZT/3TC/DTG	3.07 (1.17-8.04)	**0.023**	-	-
	ABC/3TC/DTG	1.50 (0.67-3.37)	0.325	-	-
	ABC/3TC/LPVr	2.94 (1.24-6.95)	**0.014**	-	-
	TDF/3TC/ATVr	3.17 (0.66-15.24)	0.149	-	-
	AZT/3TC/ATVr	2.70 (0.85-8.60)	0.093	-	-
	OTHERS	3.81 (1.47-9.86)	**0.006**	-	-
VL Leading to the HIVDR test (copies/ml)	1,000-9,999	Referent		-	-
	10,000-99,999	1.81 (0.98-3.34)	0.060	-	-
	100,000-999,000	0.99 (0.50-1.95)	0.968	-	-
	1,000,000 +	3.68 (0.44-30.83)	0.229	-	-
Treatment Line	First line	Referent		-	-
	Second line	2.45 (1.41-4.26)	**0.001**	-	-
	Third line	5.97 (0.75-47.54)	0.092	-	-
HIVDR Indication	Children failing on 1st line	3.52 (1.35-9.21)	**0.01**	*4.85 (0.92 - 25.56)*	*0.063*
	Adolescent failing on 1st line	2.44(1.08-5.53)	**0.033**	***4.60 (1.21-17.43)***	***0.025****
	Adult failing on 1st Line	Referent		-	-
	Patients failing on 2nd Line	4.13 (2.17-7.89)	**0.000**	***3.91 (1.25-12.20)***	***0.019****
	Patient failing on 3rd line	10.06 (1.23-82.33)	**0.031**	***10.95 (1.02-117.50)***	***0.048****
WHO clinical stage	I/II	Referent		-	-
	III/IV	1.64 (0.78-3.46)	0.189	*2.09 (0.89-4.90)*	*0.09*
Year of Sample collection	2021	Referent			
	2022	0.58 (0.18 - 1.92)	0.377	*0.48 (0.14 – 1.66)*	*0.246*
	2023	0.29 (0.08 - 0.58)	**0.002**	0.21 (0.07 -	**0.01***

				0.69)	

*** Statistically significant variables with p ≤0.05**

Discussion

We set out to estimate the prevalence of HIVDR, describe common mutations, and associated factors among non-suppressed PLHIV in the West Nile region of Uganda. We found that 73.9% had at least one mutation. The commonest mutations were the NNRTI mutations mostly K103N/S and G190A/S/E. The associated factors were indication for the HIVDR test, duration on ART and the year of HIVDR sample collection.

The observed prevalence (73.9%) is below the global and African estimates of 83.5% found in a study by WHO in eight countries that included adult PLHIV on ART for four or more years (9). It is also below what was found in a Ugandan study among 1,064 adult participants on first line for ≥ 48 months that found a prevalence of 90.4% (10). Estimates from neighboring countries of Rwanda and Kenya with 92.7% and 82.3% respectively were found in a study that included 500 PLHIV that were failing on first line (22, 23). We postulate that the lower prevalence we found can be explained by the suboptimal adherence associated with intermittent drug use within the region which could lead to viral failure without sufficient selective pressure to drive resistance mutations. This means continued nonadherence will lead to mutations among the PLHIV and improved adherence is likely to prevent development of mutations (7).

The commonest NNRTI mutations (K103N/S and G190A/S/E) found in 66% of the participants confer resistance to efavirenz and nevirapine with a single mutation conferring resistance to all first-generation drugs (24-26). These two drugs were part of the recommended first line drugs in Uganda until 2018 (21). The high rates of NNRTI resistance is consistent with other studies conducted in similar settings such as Uganda (84.6%), Rwanda (90.4%), Kenya (81%) amongst

PLHIV failing on treatment (9, 10, 22, 23). The high rate of etravirine resistance (27%) conferred by mutations such as G190A/S and Y181C is likely to limit third line treatment options (27). The high rates of M184V/I mutations (50%) from NRTIs is attributed to continued usage of lamivudine as a backbone in all regimens in SSA since the presence of this mutation reduces the viral replicative fitness and increases susceptibility to Tenofovir and Zidovudine (AZT) (28). The prolonged use of AZT including currently as part of the recommended second line of treatment in Uganda explains the high prevalence of TAMs (26%) among participants (27). The lower mutation rates in PIs (16%) and INSTI (14%) is due the higher genetic barrier to resistance of boosted PI-based ART and INSTIs (29) and the fact that INSTIs have just recently been introduced into the HIV program as first line drugs and participants have been exposed to them for a shorter time (21). Other studies reported similar low prevalences: a review of 20 studies in 11 SSA countries (PI resistance 17%) (30) and a review of 88 publications worldwide (INSTI resistance 1.5%) among ART-experienced PLHIV (31). The mutations mainly spared darunavir (5%) the most commonly used drug in third line of treatment, however, the dolutegravir resistance of 12% is high for a drug with a high genetic barrier to resistance and that only been recently scaled up (21). It is an issue of concern to be noted by the program since it is likely to limit HIV treatment options (27). This increasing resistance could be due to unintended DTG dual or monotherapy due to failure of other low genetic barrier NRTIs within the treatment regimen which greatly increases the risk of resistance (32, 33). The association between duration on ART and HIVDR is supported by the notion that prolonged ART exposure increases the risk of emergence of acquired drug resistant mutations (34) and could also be a reflection of the time an individual has spent on a suboptimal regimen or with adherence challenges which are associated with insufficient drug pressure in the body which leads to HIVDR (35). A systematic

review of seven studies conducted in Africa, Asia and south America found a similar association (36) while other similar studies in Uganda and Rwanda didn't find any association (12, 23). For the indication for the HIVDR test, factors such as peer pressure, stigma and discrimination, drug and alcohol abuse and non-disclosure stand out amongst adolescents leading to poor adherence (27) and hence development HIVDR while participants on second-line and third-line of treatment have spent a longer time on treatment and have also undergone prior regimen changes due to probable or confirmed HIVDR respectively (34). Addressing adherence challenges amongst adolescents mainly through peer support and adolescent friendly services will be key in prevention of HIVDR (36). Prior to 2023, the eligibility criteria for a HIVDR test in Uganda included only PLHIV failing on either second or third line of treatment, however, in 2023 the criteria was changed to include all PLHIV with treatment failure irrespective of the treatment line. This meant that tests conducted in 2023 following the change in eligibility criteria were less likely to have developed HIVDR since they had been on a failing regimen for a short duration (27).

The study has a larger sample size of participants compared to previous studies conducted within Uganda and has resistance data against INSTIs which were not present in the country. Our study has one limitation that the HIVDR data prior to current ART-regimen initiation was not available so we could not rule out the possibility of transmitted drug resistance that existed prior to ART initiation.

Conclusion

The study found a lower prevalence of drug-resistant mutations amongst PLHIV failing on ART and the HIVDR mutations were lower among the INSTI and PI drug classes. However, a relatively high rate of DTG resistance was obtained. The most significant predictor of HIVDR mutations was ART treatment duration. Close surveillance of HIVDR, adherence support, low

level viremia tracking, regimen optimization, timely switching of failing clients and tracking of early warning indicators for HIVDR is essential to prevent the further emergence and spread of resistant strains**.** Additional research assessing the prevalence of transmitted drug resistance, or association between other factors like socio-cultural, viral and structural and HIVDR are recommended.

Acknowledgement

The authors extend their gratitude to the Ugandan Ministry of Health, the Makerere University School of Public Health, and the Infectious Diseases Institute for supporting this research. Special thanks to the Central Public Health Laboratories for their role in HIV drug resistance testing.

References:

1. UNAIDS. 2024 global AIDS report — The Urgency of Now: AIDS at a Crossroads. Geneva: UNAIDS; 2024 22 JULY 2024.
2. WHO GLOBAL HEALTH OBSERVATORY [Internet]. WHO. 2024. Available from: https://www.who.int/data/gho/data/themes/hiv-aids?utm_source=chatgpt.com.
3. UNAIDS. UNAIDS DATA 2024. Geneva: UNAIDS; 2024.
4. Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach: World Health Organization; 2021.
5. UPHIA. Uganda population-based HIV impact assessment report 2020. 2021.
6. WHO. Global action plan on HIV drug resistance 2017-2021. Geneva: World Health Organization; 2017 November 2021.
7. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292-307.
8. WHO. Global Price Reporting Mechanism. WHO: World Health Organization; 2017 7th July 2017.
9. WHO. HIV drug resistance report 2021. Geneva: World Health Organization; 2021.

10. Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S, et al. Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. Journal of Antimicrobial Chemotherapy. 2020;75(5):1280-9.

11. von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, et al. HIV-1 drug resistance among Ugandan adults attending an urban out-patient clinic. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2018;78(5):566-73.

12. Omooja J, Nannyonjo M, Sanyu G, Nabirye SE, Nassolo F, Lunkuse S, et al. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. J Antimicrob Chemother. 2019;74(10):3021-9.

13. Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. AIDS Res Ther. 2020;17(1):2.

14. SSHAP. Cross-border dynamics and healthcare in West Nile, Uganda. Social Science in Humanitarian Action; 2019.

15. UBOS. Multidimensional poverty index report 2022. Uganda Beaural of statistics; 2022.

16. Uganda refugees and asylum seekers population by district [Internet]. UNHCR. 2023. Available from: https://data.unhcr.org/en/country/uga

17. 106a- HIV quarterly report [Internet]. 2023 [cited 5th January 2024]. Available from: https://hmis.health.go.ug/dhis-web-commons/security/login.action#/.

18. Namaganda MM, Sendagire H, Kateete DP, Kigozi E, Luutu Nsubuga M, Ashaba Katabazi F, et al. Next-generation sequencing (NGS) reveals low-abundance HIV-1 drug resistance mutations among patients experiencing virological failure at the time of therapy switching in Uganda. F1000Research. 2022;11:901.

19. Uganda HIV drug resistance dashboard [Internet]. 2023. Available from: https://hivdr.cphluganda.org/drResults/drResults?filter=amplified

20. HIV drug resistance database: Mutation analysis [Internet]. 2023 [cited 5/01/2024]. Available from: https://hivdb.stanford.edu/hivdb/by-patterns/.

21. MOH. Consolidated guidelines for prevention and treatment of HIV in Uganda. 2018.

22. Scriven YA, Mulinge MM, Saleri N, Luvai EA, Nyachieo A, Maina EN, et al. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study. Medicine (Baltimore). 2021;100(40):e27460.

23. Musengimana G, Tuyishime E, Kiromera A, Malamba SS, Mulindabigwi A, Habimana MR, et al. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey. Antivir Ther. 2022;27(3):13596535221102690.

24. Luber AD. Genetic barriers to resistance and impact on clinical response. MedGenMed. 2005;7(3):69.

25. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS. 2005;19(3):135-40.

26. Landman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, et al., editors. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. 11th Conference on Retroviruses and Opportunistic Infections; 2004.

27. MOH. Consolidated guidelines for prevention and treatment of HIV in Uganda. . 2022.

28. Miller V, Stark T, Loeliger A, Lange J. The impact of the M184V substitution in HIV□1 reverse transcriptase on treatment response. HIV medicine. 2002;3(2):135-45.

29. Fun A, Wensing AM, Verheyen J, Nijhuis M. Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012;9:1-14.

30. Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, et al. Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clinical infectious diseases. 2018;66(12):1846-57.

31. Chu C, Tao K, Kouamou V, Avalos A, Scott J, Grant PM, et al. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review. Viruses. 2024;16(3):399.

32. Redzheb Z. Dolutegravir resistance is rare, but some risk factors can up the odds [News Article]. https://www.aidsmap.com/news/dec-2023/dolutegravir-resistance-rare-some-risk-

factors-can-odds: Aidsmap; 2023 [updated 17th January 2025; cited 2025 17th January 2025]. Available from: https://www.aidsmap.com/news/dec-2023/dolutegravir-resistance-rare-some-risk-factors-can-odds.

33. Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. The Lancet HIV. 2023;10(11):e733-e41.

34. Liu H, Ma Y, Su Y, Smith MK, Liu Y, Jin Y, et al. Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. Clinical Infectious Diseases. 2014;59(10):1495-502.

35. Rusconi S. The impact of adherence to HIV/AIDS antiretroviral therapy on the development of drug resistance. Future Medicine; 2017. p. 239-41.

36. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antiviral therapy. 2013;18(1):115-23.

Supporting Information

S1 Fig. This is Fig 1: Enrollment study profile

S2 Fig. This is Fig 2: HIVDR mutations amongst participants


Participants with repeat non suppressed VL
N= 363
Failed genotyping
N= 68; 18%
Successfully genotyped and included in the study
N = 295; 81.3%
Participants with HIVDR
218 (73.9%)


Number of individuals with DR mutations
160
140
120
100
80
60
40
20
0
18
12
8
8
8
7
6
6
4
4
99
54
40
28
22
20
16
14
14
9
9
146
77
45
36
32
25
21
19
15
10
20
12
12
10
6
6
6
6
6
5
E138K/A
G118R
G140A/S
Q148H/R/K
T66A/I
E157Q
S147G
R263K
L74M
H51Y
K103N
G190A/S
A98G
Y181C/V
P225H
K101E/P
E138A/G/K
V108I
Y188L
K238T
K103S
M184V
TAMS
T215F/Y
M41L
K70R
D67N
L210W
K219Q/E
L74V/I
K219T
M46I
I54IT/V
K20T
V82A
I50L/V
Q58E
L33F
L76V
L10F
I47A/T/V
INSTI
NNRTI
NRTI
PI